EpiPen Maker Slams Sanofi's Bid To Exit Antitrust MDL
Sanofi should not yet be allowed to leave multidistrict litigation to pursue claims elsewhere that EpiPen maker Mylan used anti-competitive practices to hurt sales of Sanofi's competing emergency allergy treatment, Mylan...To view the full article, register now.
Already a subscriber? Click here to view full article